{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:26:03Z","timestamp":1773325563575,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.psychres.2004.01.010","type":"journal-article","created":{"date-parts":[[2004,7,21]],"date-time":"2004-07-21T17:57:43Z","timestamp":1090432663000},"page":"227-235","source":"Crossref","is-referenced-by-count":31,"title":["Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes"],"prefix":"10.1016","volume":"127","author":[{"given":"Michael","family":"Segal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Avital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Hausvater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Sandbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Moguillansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2004.01.010_BIB1","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Supplement 4","key":"10.1016\/j.psychres.2004.01.010_BIB2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-9338(03)00075-0","article-title":"Recent evidence for dopamine abnormalities in schizophrenia","volume":"17","author":"Abi-Dargham","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.psychres.2004.01.010_BIB4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1982.04290070025006","article-title":"Negative vs. positive schizophrenia: definition and validation","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"110","key":"10.1016\/j.psychres.2004.01.010_BIB5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0165-1781(02)00037-9","article-title":"Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia","volume":"15","author":"Angelopoulos","year":"2002","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0166-2236(84)80062-4","article-title":"CNS stimulants as a tool in the study of schizophrenia","volume":"7","author":"Angrist","year":"1984","journal-title":"Trends in Neuroscience"},{"key":"10.1016\/j.psychres.2004.01.010_BIB7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00428187","article-title":"Amphetamine response and relapse risk after depot neuroleptic discontinuation","volume":"85","author":"Angrist","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0920-9964(99)00195-4","article-title":"Inverse correlation between hallucinations and serum prolactin in patients with non-affective psychoses","volume":"44","author":"Appelberg","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacologica and Toxicologica"},{"key":"10.1016\/j.psychres.2004.01.010_BIB10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1176\/ajp.135.2.164","article-title":"Antipsychotic drugs, neurotransmitters and schizophrenia","volume":"135","author":"Carlsson","year":"1978","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-1781(98)00085-7","article-title":"Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder","volume":"81","author":"Chou","year":"1998","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"19","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.psychres.2004.01.010_BIB13","first-page":"22","article-title":"Two dimensions of pathology in schizophrenia: dopaminergic and non-dopaminergic","volume":"18","author":"Crow","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.psychres.2004.01.010_BIB14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0006-3223(86)90124-1","article-title":"Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics","volume":"7","author":"Csernansky","year":"1986","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archpsyc.1985.01790260053006","article-title":"Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems","volume":"42","author":"Davis","year":"1985","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2004.01.010_BIB16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/ajp.144.7.934","article-title":"l-Dopa challenge and relapse in schizophrenia","volume":"144","author":"Davidson","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1176\/ajp.130.10.1088","article-title":"Evolving behavior in the clinical and experimental amphetamine (model) psychosis","volume":"130","author":"Ellinwood","year":"1973","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB19","first-page":"151","article-title":"Serum neuroleptic levels, prolactin levels, and relapse: a 2-year study of schizophrenic outpatients","volume":"48","author":"Faraone","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archpsyc.1991.01810350009002","article-title":"Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic and undifferentiated schizophrenia","volume":"48","author":"Fenton","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/oxfordjournals.schbul.a006885","article-title":"Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities","volume":"27","author":"Finlay","year":"2001","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2004.01.010_BIB23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0006-3223(89)90034-6","article-title":"The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia","volume":"26","author":"Glazer","year":"1989","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic vs. tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia","volume":"4","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.psychres.2004.01.010_BIB25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0165-1781(90)90026-2","article-title":"Prolactin shifts after neuroleptic withdrawal","volume":"32","author":"Green","year":"1990","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB26","unstructured":"IMx Prolactin assay. Abott Laboratories, 1997. Diagnostic Division: 1\u201311"},{"key":"10.1016\/j.psychres.2004.01.010_BIB27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0278-5846(99)00103-7","article-title":"Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics","volume":"24","author":"Kaneda","year":"2000","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia","volume":"160","author":"Kapur","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2004.01.010_BIB31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0006-3223(94)00114-I","article-title":"Basal and haloperidol-stimulated prolactin and symptoms of non-affective and affective psychoses in neuroleptic-free men","volume":"37","author":"Keks","year":"1995","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-3223(92)90067-A","article-title":"Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients","volume":"32","author":"Kirkpatrick","year":"1992","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-1781(88)90094-7","article-title":"Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients","volume":"25","author":"Kirch","year":"1988","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1192\/bjp.171.6.574","article-title":"Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia","volume":"171","author":"Knable","year":"1997","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/oxfordjournals.schbul.a033332","article-title":"Heterogeneity of the psychoses: is there a neurodegenerative psychosis?","volume":"24","author":"Knoll","year":"1998","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2004.01.010_BIB36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/026988119901300405","article-title":"Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies","volume":"13","author":"Laruelle","year":"1999","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1176\/ajp.141.5.633","article-title":"Methylphenidate challenge as a predictor of relapse in schizophrenia","volume":"141","author":"Lieberman","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1037\/0022-006X.49.3.438","article-title":"The Maine Scale of Paranoid and Non-paranoid Schizophrenia: reliability and validity","volume":"49","author":"Magaro","year":"1981","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","article-title":"Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses","volume":"51","author":"Melkersson","year":"2001","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archpsyc.1974.01760160102021","article-title":"Serum prolactin levels in unmedicated schizophrenic patients","volume":"31","author":"Meltzer","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstr\u00f6m","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.368","article-title":"Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia","volume":"17","author":"Oades","year":"2002","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB45","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0278-5846(96)00132-7","article-title":"Plasma prolactin concentration and psychopathology of schizophrenia","volume":"20","author":"Otani","year":"1996","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1192\/bjp.161.3.335","article-title":"Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy","volume":"161","author":"Peralta","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB47","series-title":"Psychopharmacology: The Third Generation of Progress","first-page":"803","article-title":"Prolactin and schizophrenia","author":"Rubin","year":"1987"},{"key":"10.1016\/j.psychres.2004.01.010_BIB48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1176\/appi.ajp.159.5.713","article-title":"Schizophrenia: reproductive hormones and the brain","volume":"159","author":"Stevens","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB49","first-page":"233","article-title":"Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment","volume":"17","author":"van Kammen","year":"1982","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB50","first-page":"357","article-title":"Serum prolactin as a correlate of clinical response to haloperidol","volume":"11","author":"Van Putten","year":"1991","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2004.01.010_BIB51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0165-1781(01)00256-6","article-title":"Lower prolactin bioactivity in unmedicated schizophrenic patients","volume":"102","author":"Warner","year":"2001","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2004.01.010_BIB52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1176\/ajp.153.3.346","article-title":"Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms","volume":"153","author":"Wolkin","year":"1996","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2004.01.010_BIB53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0165-1781(02)00022-7","article-title":"Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia","volume":"109","author":"Zhang","year":"2002","journal-title":"Psychiatry Research"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178104000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178104000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T17:54:14Z","timestamp":1549389254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178104000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0165178104000848"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2004.01.010","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}